Hypoglycemia – a condition in which low blood glucose levels can cause you to feel dizzy, weak, and shaky – can catch you by ...

MIT engineers have developed a tiny implantable device that could revolutionize emergency treatment for people with Type 1 ...

For individuals with type 1 diabetes – an autoimmune condition – maintaining stable blood sugar is a constant challenge.

DelveInsight’s, “Diabetes Pipeline Insight 2025” report provides comprehensive insights about 200+ companies and 200+ ...

In T1D, autoantibodies destroy the pancreatic beta cells, insulin release is diminished, and glucagon release is excessive relative to the insulin deficiency. This can cause a vicious cycle of ...

As glycogen reserves dwindle, the body begins to break down fats through glucagon-driven lipolysis . At the same time, ...

Patients with type 2 diabetes secrete not only too little insulin but also too much glucagon, which contributes to poor blood glucose control. Skip to content. Menu. Medical Home Life Sciences Home.

Insulin has been proposed to inhibit the release of glucagon 13. In theory, substances found in insulin granules, such as islet amyloid polypeptide, zinc, ATP and possibly glutamate, could all be ...

Glucagon responses to hypoglycemia have been known to be blunted in type 1 diabetes of long duration, and this may be a result of a loss of alpha- and beta-cell communication secondary to insulin ...

Conclusions—We concluded that insulin stimulation (day 4) and glucagon inhibition (day 3) contribute equally to the effect of GLP-1 on glucose turnover in patients with type 2 diabetes, and ...

To test the method, the team fused glucagon-like peptide-1 (GLP-1), a hormone that regulates the release of insulin, with a genetically engineered heat sensitive polymer to create the POD.